Akili, a company providing video game-like digital therapeutics for ADHD, has entered a merger agreement with Virtual Therapeutics in a $34 million deal. Akili shareholders will receive $0.4340 per share in cash. After the merger, the combined companies will operate under the Virtual Therapeutics brand. Akili CEO Matt Franklin believes this move will create a strong platform to address mental health needs. Akili had previously announced seeking strategic alternatives to maximize shareholder value, which included reducing its workforce and restructuring. The company reported a decrease in revenue and increased operating expenses in the first quarter of 2024 compared to the previous quarter.
Source link
Akili to merge with Virtual Therapeutics in $34M deal
